AVI 5126

Drug Profile

AVI 5126

Alternative Names: AVI-5126; GTX 5126; Restin-CP

Latest Information Update: 27 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AVI BioPharma
  • Developer AVI BioPharma; Global Therapeutics
  • Class Vascular disorder therapies
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 01 Jun 2010 Discontinued - Phase-II for Coronary artery restenosis in Germany (Intracoronary)
  • 01 Jun 2010 Cook terminates a phase II trial [NCT00777842] in Coronary artery restenosis in Germany
  • 11 Nov 2008 Phase II clinical trials in Coronary artery restenosis in Germany (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top